

18 - numbered claims

AR 9/18/04

Appl. No. 09/744,441

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) An isolated antagonist of the ~~a~~ ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine and comprising the amino acid sequence Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH<sub>2</sub>, wherein Xaa<sub>1</sub> is a neutral amino acid, and Xaa<sub>2</sub> is a charged amino acid.
2. (Currently Amended) The isolated antagonist of claim 1 lacking the 10 N-terminal amino acids of native sauvagine.
3. Canceled
- 3  
4. (Currently Amended) The isolated antagonist of claim 3<sub>1</sub>, wherein Xaa<sub>1</sub> is a hydrophobic amino acid, and Xaa<sub>2</sub> is Glu or His.
- 4  
5. (Currently Amended) The isolated antagonist of claim 4<sub>3</sub>, wherein Xaa<sub>1</sub> is Leu.
6. (Currently Amended) The isolated antagonist of claim 3<sub>1</sub>, wherein Xaa<sub>1</sub> is a polar amino acid, and Xaa<sub>2</sub> is Glu or His.
7. (Currently Amended) The isolated antagonist of claim 6, wherein Xaa<sub>1</sub> is Tyr.
- 9  
8. (Currently Amended) The isolated antagonist of claim 3<sub>1</sub>, wherein Xaa<sub>1</sub> is in the D-configuration.
- 10  
9. (Currently Amended) The isolated antagonist of claim 8<sub>9</sub>, wherein Xaa<sub>1</sub> is D-Leu.
- 11  
10. (Currently Amended) The isolated antagonist of claim 8<sub>9</sub>, wherein Xaa<sub>1</sub> is D-Tyr.

Appl. No. 09/744,441

- 5  
11. (Currently Amended) The isolated antagonist of claim <sup>4</sup>5, wherein Xaa<sub>2</sub> is Glu.
12. (Currently Amended) The isolated antagonist of claim <sup>9</sup>8, wherein Xaa<sub>1</sub> is D-Phe.
- 8  
13. (Currently Amended) The isolated antagonist of claim 7, wherein Xaa<sub>2</sub> is His.
- 16  
14. (Currently Amended) An isolated antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acid of native sauvagine, wherein the N-terminal amino acid acids of said antagonist is a charged amino acid and comprising the amino acid sequence Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH<sub>2</sub>, wherein Xaa<sub>1</sub> is a neutral amino acid, and Xaa<sub>2</sub> is a charged amino acid.
- 17  
15. (Currently Amended) The isolated antagonist of claim <sup>16</sup>14, wherein said charged amino acid is positively charged.
- 18  
16. (Currently Amended) The isolated antagonist of claim <sup>17</sup>15, wherein said charged amino acid is His.
- 19  
17. (Currently Amended) The isolated antagonist of claim <sup>16</sup>14 which comprises a phenyldiazirine group coupled to the N-terminal amino acid of said antagonist.
- 20  
18. (Currently Amended) The isolated antagonist of claim <sup>19</sup>17, wherein said phenyldiazirine group is a 4-(1-azi-2,2,2-trifluoroethyl)benzoyl (ATB)-group.
19. Canceled
20. Canceled

Appl. No. 09/744,441

21. Canceled

22. Canceled

23. Canceled

24. Canceled

25. Canceled

26. Canceled

13  
27. (Currently Amended) A pharmaceutical composition comprising the antagonist of claim 1, ~~the polynucleotide of claim 19, the vector of claim 20, the antibody of claim 25 and/or the anti-idiotypic antibody of claim 26~~ and optionally a pharmaceutically acceptable carrier and/or diluent.

28. Canceled

14  
29. (Currently Amended) A kit comprising  
(a) — an antagonist of claim 1;  
(b) — ~~the polynucleotide of claim 19;~~  
(c) — ~~the vector of claim 20;~~  
(d) — ~~the antibody of claim 25; and/or~~  
(e) — ~~the anti-idiotypic antibody of claim 26.~~

30. Canceled

15  
31. (Previously Presented) The antagonist of claim 1, wherein said CRFR2 is CRFR2 $\alpha$  or CRFR2 $\beta$ .

AUG. 2. 2004 1:39PM BSKB COM

NO. 2767 P. 8

Appl. No. 09/744,441

32. Canceled

33. Canceled